Absci offers asymmetric AI-biologic upside through ABS-201 and platform partnerships, but at $9.25 the probability-weighted five-year value of $7.91 implies investors are already paying for clinical success.
Overview
Absci Corporation is a clinical-stage biopharmaceutical company attempting to transform antibody discovery by integrating generative AI, synthetic biology, and translational medicine. Its Integrated Drug Creation platform creates de novo antibodies from target sequence or structural data and combines Origin-1 models with SoluPro wet-lab screening. The model has two paths: advance proprietary assets such as ABS-201 and ABS-101 toward clinical value inflection, while generating partner revenue through access fees, research services, milestones, and potential royalties. **The central near-term catalyst is ABS-201**, which showed favorable blinded Phase 1 safety data with zero serious adverse events across 32 volunteers and an estimated half-life of at least 65 days. Twelve- to 26-week AGA efficacy data are expected in H2 2026 and early 2027. Financially, Q2 2026 revenue fell 46.4% year over year to $0.32 million, net loss widened to $33.21 million, and R&D increased to $22.60 million, but $201.1 million of liquidity provides runway into H2 2028. At $9.25, the company carries a $1.587 billion market capitalization, $1.386 billion EV, and approximately 1,015x TTM P/S, so valuation reflects clinical and platform option value rather than current cash flows. Analyst targets average $14.15–$14.28, but the probability-weighted five-year value is $7.91.